Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment
Highlights • Clinically significant anaemia was detected in HCV patients receiving protease inhibitor + peg-interferon + ribavirin. • Univariate analysis showed that SLC28A2 rs11854484 and ITPA rs1127354 polymorphisms plays a critical role in anaemia outcome. • Anaemia represents the most frequent c...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical virology 2015-07, Vol.68, p.56-60 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 60 |
|---|---|
| container_issue | |
| container_start_page | 56 |
| container_title | Journal of clinical virology |
| container_volume | 68 |
| creator | Ampuero, Javier Del Campo, José Antonio Rojas, Lourdes Calleja, José Luis Cabezas, Joaquín Lens, Sabela Crespo, Javier Forns, Xavier Andrade, Raúl J Fernández, Inmaculada Buti, María Millán, Raquel Romero-Gómez, Manuel |
| description | Highlights • Clinically significant anaemia was detected in HCV patients receiving protease inhibitor + peg-interferon + ribavirin. • Univariate analysis showed that SLC28A2 rs11854484 and ITPA rs1127354 polymorphisms plays a critical role in anaemia outcome. • Anaemia represents the most frequent cause for the discontinuation of therapy in patients with chronic hepatitis C infection. • We established a protective haplotype combining ITPA rs1127354 and SLC28A2 rs11854484 genotypes. • These findings could optimize the management of treatment-induced anaemia in hepatitis C infection. |
| doi_str_mv | 10.1016/j.jcv.2015.05.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1701498563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1386653215001559</els_id><sourcerecordid>1701498563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-a2b1d6491c5a1dc31c96831d467825724aadae00e65f38aeaf4bc2d8c44871813</originalsourceid><addsrcrecordid>eNqFksGKFDEQhhtR3HX1AbxIjl56NpV0p9MIwjCsujCguOs51KSrd9L2pMckM7Jv4uOaZtY9eFAoSAjf_1eov4riNfAFcFCXw2Kwx4XgUC94LuBPinPQjSzrVjVP811qVapairPiRYwDz6CsmufFmVC8ASmb8-LX12kkNvXs-vbLkqHv2M16JfRSsDvyFJnzLG2J7QN1ziY3-ZlFj7RzyDDGyTpM1LGfLm0zNSXCSFm1dRuXpsD24yGy4DZ4dCF7zQ32dOd8otBTyHb5cUt7TC65yFYsBcK0I59eFs96HCO9ejgvim8frm5Xn8r154_Xq-W6tFUFqUSxgU5VLdgaobMSbKu0hK5SjRZ1IyrEDolzUnUvNRL21caKTme1bkCDvCjennzz538cKCazc9HSOKKn6RANNByqVtdK_h9VWnPeCDW7wgm1YYoxUG_2we0w3BvgZs7ODCZnZ-bsDM8FPGvePNgfNjvqHhV_wsrAuxNAeR5HR8FE68jbHE0gm0w3uX_av_9LbUfnncXxO91THKZD8HnQBkwUhpubeXnm3YF63pu6lb8BSkK_TQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1688007261</pqid></control><display><type>article</type><title>Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Ampuero, Javier ; Del Campo, José Antonio ; Rojas, Lourdes ; Calleja, José Luis ; Cabezas, Joaquín ; Lens, Sabela ; Crespo, Javier ; Forns, Xavier ; Andrade, Raúl J ; Fernández, Inmaculada ; Buti, María ; Millán, Raquel ; Romero-Gómez, Manuel</creator><creatorcontrib>Ampuero, Javier ; Del Campo, José Antonio ; Rojas, Lourdes ; Calleja, José Luis ; Cabezas, Joaquín ; Lens, Sabela ; Crespo, Javier ; Forns, Xavier ; Andrade, Raúl J ; Fernández, Inmaculada ; Buti, María ; Millán, Raquel ; Romero-Gómez, Manuel</creatorcontrib><description>Highlights • Clinically significant anaemia was detected in HCV patients receiving protease inhibitor + peg-interferon + ribavirin. • Univariate analysis showed that SLC28A2 rs11854484 and ITPA rs1127354 polymorphisms plays a critical role in anaemia outcome. • Anaemia represents the most frequent cause for the discontinuation of therapy in patients with chronic hepatitis C infection. • We established a protective haplotype combining ITPA rs1127354 and SLC28A2 rs11854484 genotypes. • These findings could optimize the management of treatment-induced anaemia in hepatitis C infection.</description><identifier>ISSN: 1386-6532</identifier><identifier>EISSN: 1873-5967</identifier><identifier>DOI: 10.1016/j.jcv.2015.05.010</identifier><identifier>PMID: 26071337</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adolescent ; Adult ; Adverse event ; Aged ; Allergy and Immunology ; Anaemia ; Anemia - chemically induced ; Anemia - epidemiology ; Anemia - genetics ; Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Boceprevir ; Drug Therapy, Combination - adverse effects ; Drug Therapy, Combination - methods ; Female ; Genetic Predisposition to Disease ; Hepatitis C ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Humans ; Incidence ; Infectious Disease ; ITPA ; Lead-in-phase ; Male ; Membrane Transport Proteins - genetics ; Middle Aged ; Oligopeptides - adverse effects ; Oligopeptides - therapeutic use ; Pharmacogenomics ; Polymorphism ; Proline - adverse effects ; Proline - analogs & derivatives ; Proline - therapeutic use ; Prospective Studies ; Protease Inhibitors - adverse effects ; Protease Inhibitors - therapeutic use ; Pyrophosphatases - genetics ; Ribavirin - adverse effects ; Ribavirin - therapeutic use ; Risk Assessment ; SLC28 ; Telaprevir ; Young Adult</subject><ispartof>Journal of clinical virology, 2015-07, Vol.68, p.56-60</ispartof><rights>Elsevier B.V.</rights><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-a2b1d6491c5a1dc31c96831d467825724aadae00e65f38aeaf4bc2d8c44871813</citedby><cites>FETCH-LOGICAL-c441t-a2b1d6491c5a1dc31c96831d467825724aadae00e65f38aeaf4bc2d8c44871813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jcv.2015.05.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26071337$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ampuero, Javier</creatorcontrib><creatorcontrib>Del Campo, José Antonio</creatorcontrib><creatorcontrib>Rojas, Lourdes</creatorcontrib><creatorcontrib>Calleja, José Luis</creatorcontrib><creatorcontrib>Cabezas, Joaquín</creatorcontrib><creatorcontrib>Lens, Sabela</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><creatorcontrib>Forns, Xavier</creatorcontrib><creatorcontrib>Andrade, Raúl J</creatorcontrib><creatorcontrib>Fernández, Inmaculada</creatorcontrib><creatorcontrib>Buti, María</creatorcontrib><creatorcontrib>Millán, Raquel</creatorcontrib><creatorcontrib>Romero-Gómez, Manuel</creatorcontrib><title>Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment</title><title>Journal of clinical virology</title><addtitle>J Clin Virol</addtitle><description>Highlights • Clinically significant anaemia was detected in HCV patients receiving protease inhibitor + peg-interferon + ribavirin. • Univariate analysis showed that SLC28A2 rs11854484 and ITPA rs1127354 polymorphisms plays a critical role in anaemia outcome. • Anaemia represents the most frequent cause for the discontinuation of therapy in patients with chronic hepatitis C infection. • We established a protective haplotype combining ITPA rs1127354 and SLC28A2 rs11854484 genotypes. • These findings could optimize the management of treatment-induced anaemia in hepatitis C infection.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Adverse event</subject><subject>Aged</subject><subject>Allergy and Immunology</subject><subject>Anaemia</subject><subject>Anemia - chemically induced</subject><subject>Anemia - epidemiology</subject><subject>Anemia - genetics</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Boceprevir</subject><subject>Drug Therapy, Combination - adverse effects</subject><subject>Drug Therapy, Combination - methods</subject><subject>Female</subject><subject>Genetic Predisposition to Disease</subject><subject>Hepatitis C</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Incidence</subject><subject>Infectious Disease</subject><subject>ITPA</subject><subject>Lead-in-phase</subject><subject>Male</subject><subject>Membrane Transport Proteins - genetics</subject><subject>Middle Aged</subject><subject>Oligopeptides - adverse effects</subject><subject>Oligopeptides - therapeutic use</subject><subject>Pharmacogenomics</subject><subject>Polymorphism</subject><subject>Proline - adverse effects</subject><subject>Proline - analogs & derivatives</subject><subject>Proline - therapeutic use</subject><subject>Prospective Studies</subject><subject>Protease Inhibitors - adverse effects</subject><subject>Protease Inhibitors - therapeutic use</subject><subject>Pyrophosphatases - genetics</subject><subject>Ribavirin - adverse effects</subject><subject>Ribavirin - therapeutic use</subject><subject>Risk Assessment</subject><subject>SLC28</subject><subject>Telaprevir</subject><subject>Young Adult</subject><issn>1386-6532</issn><issn>1873-5967</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFksGKFDEQhhtR3HX1AbxIjl56NpV0p9MIwjCsujCguOs51KSrd9L2pMckM7Jv4uOaZtY9eFAoSAjf_1eov4riNfAFcFCXw2Kwx4XgUC94LuBPinPQjSzrVjVP811qVapairPiRYwDz6CsmufFmVC8ASmb8-LX12kkNvXs-vbLkqHv2M16JfRSsDvyFJnzLG2J7QN1ziY3-ZlFj7RzyDDGyTpM1LGfLm0zNSXCSFm1dRuXpsD24yGy4DZ4dCF7zQ32dOd8otBTyHb5cUt7TC65yFYsBcK0I59eFs96HCO9ejgvim8frm5Xn8r154_Xq-W6tFUFqUSxgU5VLdgaobMSbKu0hK5SjRZ1IyrEDolzUnUvNRL21caKTme1bkCDvCjennzz538cKCazc9HSOKKn6RANNByqVtdK_h9VWnPeCDW7wgm1YYoxUG_2we0w3BvgZs7ODCZnZ-bsDM8FPGvePNgfNjvqHhV_wsrAuxNAeR5HR8FE68jbHE0gm0w3uX_av_9LbUfnncXxO91THKZD8HnQBkwUhpubeXnm3YF63pu6lb8BSkK_TQ</recordid><startdate>20150701</startdate><enddate>20150701</enddate><creator>Ampuero, Javier</creator><creator>Del Campo, José Antonio</creator><creator>Rojas, Lourdes</creator><creator>Calleja, José Luis</creator><creator>Cabezas, Joaquín</creator><creator>Lens, Sabela</creator><creator>Crespo, Javier</creator><creator>Forns, Xavier</creator><creator>Andrade, Raúl J</creator><creator>Fernández, Inmaculada</creator><creator>Buti, María</creator><creator>Millán, Raquel</creator><creator>Romero-Gómez, Manuel</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20150701</creationdate><title>Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment</title><author>Ampuero, Javier ; Del Campo, José Antonio ; Rojas, Lourdes ; Calleja, José Luis ; Cabezas, Joaquín ; Lens, Sabela ; Crespo, Javier ; Forns, Xavier ; Andrade, Raúl J ; Fernández, Inmaculada ; Buti, María ; Millán, Raquel ; Romero-Gómez, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-a2b1d6491c5a1dc31c96831d467825724aadae00e65f38aeaf4bc2d8c44871813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Adverse event</topic><topic>Aged</topic><topic>Allergy and Immunology</topic><topic>Anaemia</topic><topic>Anemia - chemically induced</topic><topic>Anemia - epidemiology</topic><topic>Anemia - genetics</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Boceprevir</topic><topic>Drug Therapy, Combination - adverse effects</topic><topic>Drug Therapy, Combination - methods</topic><topic>Female</topic><topic>Genetic Predisposition to Disease</topic><topic>Hepatitis C</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Incidence</topic><topic>Infectious Disease</topic><topic>ITPA</topic><topic>Lead-in-phase</topic><topic>Male</topic><topic>Membrane Transport Proteins - genetics</topic><topic>Middle Aged</topic><topic>Oligopeptides - adverse effects</topic><topic>Oligopeptides - therapeutic use</topic><topic>Pharmacogenomics</topic><topic>Polymorphism</topic><topic>Proline - adverse effects</topic><topic>Proline - analogs & derivatives</topic><topic>Proline - therapeutic use</topic><topic>Prospective Studies</topic><topic>Protease Inhibitors - adverse effects</topic><topic>Protease Inhibitors - therapeutic use</topic><topic>Pyrophosphatases - genetics</topic><topic>Ribavirin - adverse effects</topic><topic>Ribavirin - therapeutic use</topic><topic>Risk Assessment</topic><topic>SLC28</topic><topic>Telaprevir</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ampuero, Javier</creatorcontrib><creatorcontrib>Del Campo, José Antonio</creatorcontrib><creatorcontrib>Rojas, Lourdes</creatorcontrib><creatorcontrib>Calleja, José Luis</creatorcontrib><creatorcontrib>Cabezas, Joaquín</creatorcontrib><creatorcontrib>Lens, Sabela</creatorcontrib><creatorcontrib>Crespo, Javier</creatorcontrib><creatorcontrib>Forns, Xavier</creatorcontrib><creatorcontrib>Andrade, Raúl J</creatorcontrib><creatorcontrib>Fernández, Inmaculada</creatorcontrib><creatorcontrib>Buti, María</creatorcontrib><creatorcontrib>Millán, Raquel</creatorcontrib><creatorcontrib>Romero-Gómez, Manuel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ampuero, Javier</au><au>Del Campo, José Antonio</au><au>Rojas, Lourdes</au><au>Calleja, José Luis</au><au>Cabezas, Joaquín</au><au>Lens, Sabela</au><au>Crespo, Javier</au><au>Forns, Xavier</au><au>Andrade, Raúl J</au><au>Fernández, Inmaculada</au><au>Buti, María</au><au>Millán, Raquel</au><au>Romero-Gómez, Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment</atitle><jtitle>Journal of clinical virology</jtitle><addtitle>J Clin Virol</addtitle><date>2015-07-01</date><risdate>2015</risdate><volume>68</volume><spage>56</spage><epage>60</epage><pages>56-60</pages><issn>1386-6532</issn><eissn>1873-5967</eissn><abstract>Highlights • Clinically significant anaemia was detected in HCV patients receiving protease inhibitor + peg-interferon + ribavirin. • Univariate analysis showed that SLC28A2 rs11854484 and ITPA rs1127354 polymorphisms plays a critical role in anaemia outcome. • Anaemia represents the most frequent cause for the discontinuation of therapy in patients with chronic hepatitis C infection. • We established a protective haplotype combining ITPA rs1127354 and SLC28A2 rs11854484 genotypes. • These findings could optimize the management of treatment-induced anaemia in hepatitis C infection.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26071337</pmid><doi>10.1016/j.jcv.2015.05.010</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6532 |
| ispartof | Journal of clinical virology, 2015-07, Vol.68, p.56-60 |
| issn | 1386-6532 1873-5967 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1701498563 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Adolescent Adult Adverse event Aged Allergy and Immunology Anaemia Anemia - chemically induced Anemia - epidemiology Anemia - genetics Antiviral Agents - adverse effects Antiviral Agents - therapeutic use Boceprevir Drug Therapy, Combination - adverse effects Drug Therapy, Combination - methods Female Genetic Predisposition to Disease Hepatitis C Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Humans Incidence Infectious Disease ITPA Lead-in-phase Male Membrane Transport Proteins - genetics Middle Aged Oligopeptides - adverse effects Oligopeptides - therapeutic use Pharmacogenomics Polymorphism Proline - adverse effects Proline - analogs & derivatives Proline - therapeutic use Prospective Studies Protease Inhibitors - adverse effects Protease Inhibitors - therapeutic use Pyrophosphatases - genetics Ribavirin - adverse effects Ribavirin - therapeutic use Risk Assessment SLC28 Telaprevir Young Adult |
| title | Role of ITPA and SLC28A2 genes in the prediction of anaemia associated with protease inhibitor plus ribavirin and peginterferon in hepatitis C treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T01%3A11%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20ITPA%20and%20SLC28A2%20genes%20in%20the%20prediction%20of%20anaemia%20associated%20with%20protease%20inhibitor%20plus%20ribavirin%20and%20peginterferon%20in%20hepatitis%20C%20treatment&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Ampuero,%20Javier&rft.date=2015-07-01&rft.volume=68&rft.spage=56&rft.epage=60&rft.pages=56-60&rft.issn=1386-6532&rft.eissn=1873-5967&rft_id=info:doi/10.1016/j.jcv.2015.05.010&rft_dat=%3Cproquest_cross%3E1701498563%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1688007261&rft_id=info:pmid/26071337&rft_els_id=1_s2_0_S1386653215001559&rfr_iscdi=true |